Zhejiang Shapuaisi Pharmaceutical Hits Day Low Amid Price Pressure at CNY 6.24

Zhejiang Shapuaisi Pharmaceutical Co. experienced significant volatility on March 23, 2026, with the stock declining by 8.58% and reaching an intraday low of CNY 6.24. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by 3.63% on the same day. Over the past week, Zhejiang Shapuaisi has seen a decline of 12.15%, and its performance over the last month shows a drop of 14.77%. Year-to-date, the stock has decreased by 14.54%, while its one-year performance reflects a loss of 12.27%. In a longer-term view, the stock has underperformed significantly, with a three-year decline of 20.18% and a staggering 71.44% drop over the past decade. Financial metrics indicate challenges for the company, including a low Return on Capital Employed (ROCE) of 1.63% and a negative trend in net sales growth. The company has reported negative results for six consecutive quarters, highlighting ongoing operational difficulties. With a market capitalization of CNY 2,194 million, Zhejiang Shapuaisi remains a small-cap player in the pharmaceuticals and biotechnology sector.